dr Przemysław Danek

dr Przemysław Danek

+48 12 6623389
Stanowisko: Asystent
pokój 3.3
Zakład Farmakokinetyki i Metabolizmu Leków

Dokonania naukowe

  • Publikacje

The Influence of Long-Term Treatment with Asenapine on Liver Cytochrome P450 Expression and Activity in the Rat. The Involvement of Different Mechanisms

Autorzy: Przemysław Jan Danek, Ewa Bromek, Władysława A. Daniel

DOI: 10.3390/ph14070629
Date: 2021-06-01

P.674 Chronic treatment with the atypical neuroleptic asenapine decreases the cytochrome P450 expression and activity in the liver

Autorzy:

DOI: 10.1016/j.euroneuro.2020.09.497
Date: 2020-11-01

The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions

Autorzy:

DOI: 10.1007/s43440-020-00102-5
Date: 2020-04-11

In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug–drug interactions

Autorzy:

DOI: 10.1007/s43440-020-00089-z
Date: 2020-03-26

P.103 The effect of chronic treatment with the asenapine on the cytochrome P450 2D (CYP2D) activity in different brain areas

Autorzy:

DOI: 10.1016/j.euroneuro.2019.12.004
Date: 2020-02-01

Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy

Autorzy: Danek, P.J., Wójcikowski, J., Daniel, W.A.

DOI: 10.1016/j.taap.2020.115239
Date: 2020-01-01

Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4

Autorzy: Danek, P.J., Basińska-Ziobroń, A., Wójcikowski, J., Daniel, W.A.

DOI: 10.1007/s43440-020-00157-4
Date: 2020-01-01

Clozapine and levomepromazine induce the cytochrome P450 isoenzyme CYP3A4, but not CYP1A1/2, in human hepatocytes

Autorzy:

DOI: 10.1016/s0924-977x(17)31646-2
Date: 2017-10-01

Zobacz także